"Blood Component Removal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
| Descriptor ID |
D001781
|
| MeSH Number(s) |
E02.120
|
| Concept/Terms |
Blood Component Removal- Blood Component Removal
- Blood Component Removals
- Component Removal, Blood
- Component Removals, Blood
- Removal, Blood Component
- Removals, Blood Component
- Pheresis
- Phereses
- Apheresis
- Aphereses
|
Below are MeSH descriptors whose meaning is more general than "Blood Component Removal".
Below are MeSH descriptors whose meaning is more specific than "Blood Component Removal".
This graph shows the total number of publications written about "Blood Component Removal" by people in this website by year, and whether "Blood Component Removal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 2008 | 2 | 2 | 4 |
| 2012 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Blood Component Removal" by people in Profiles.
-
Current advances in transfusion medicine 2021: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion. 2022 07; 62(7):1435-1445.
-
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107.
-
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Curr Atheroscler Rep. 2020 07 25; 22(9):48.
-
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 04; 5(4):280-290.
-
Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. Transfusion. 2016 Apr; 56(4):893-8.
-
Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections. Transfusion. 2015 Aug; 55(8):2001-9.
-
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant. 2013 Jun; 48(6):777-81.
-
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut. 2013 Sep; 62(9):1288-94.
-
Patch annulo-aortoplasty in an adult patient with congenital supravalvular aortic stenosis and a small aortic annulus. Gen Thorac Cardiovasc Surg. 2011 Aug; 59(8):569-71.
-
Bombay blood type and use of red cell apheresis during pregnancy. Obstet Gynecol. 2011 Feb; 117(2 Pt 2):463-465.